Electronics
Computer Hardware
Therapy

Brainstorm Cell Therapeutics

$4.04
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.02 (0.50%) Today
+$0.02 (0.50%) Today

Why Robinhood?

You can buy or sell BCLI and other stocks, options, ETFs, and crypto commission-free!

About

Brainstorm Cell Therapeutics, Inc. operates as a biotechnology company, which develops and commercializes adult stem cell therapeutic products. It focuses on utilizing the patients own bone marrow stem cells to generate neuron-like cells that may provide an effective treatment initially for amyotrophic lateral sclerosis, Parkinson's disease, multiple sclerosis and spinal cord injury. Read More The company was founded on September 22, 2000 and is headquartered in New York, NJ.

Employees
24
Headquarters
New York, New Jersey
Founded
2000
Market Cap
83.22M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
82.08K
High Today
$4.05
Low Today
$4.00
Open Price
$4.03
Volume
18.92K
52 Week High
$5.35
52 Week Low
$2.92

Collections

Electronics
Computer Hardware
Therapy
Biotechnology
Health
US
North America

News

Markets InsiderMar 14

BrainStorm Announces First Patient Enrolled in Phase 2 Clinical Trial of Progressive MS

NEW YORK and CLEVELAND, March 14, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. ( NASDAQ: BCLI ), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today that the first patient has been enrolled in its Phase 2 open-label, multicenter study of repeated intrathecal administration of autologous MSC-NTF cells in participants with progressive Multiple Sclerosis (MS). Chaim Lebovits, president and CEO of BrainStorm stated,...

119
MarketBeatMar 7

Stock Price, News, & Analysis for Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes a patient's own cells, which are engineered outside the body, to produce and secrete factors known to promote neuronal survival. It is developing NurOwn ...

10
Markets InsiderMar 7

BrainStorm to Host Business Update Conference Call

NEW YORK, March 07, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. ( NASDAQ: BCLI ), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, will hold a conference call on Tuesday, March 12th, at 08:30am Eastern Daylight Time, to update shareholders on the Company’s overall business developments. Tuesday, March 12, 2018 @ 8:30am Eastern Daylight Time US Toll Free: 1-877-423-9813 Toll/International: 1-201-689-8573 Israel Toll Free:...

85

Earnings

-$0.32
-$0.21
-$0.09
$0.02
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.14 per share
Actual
Expected Mar 25, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.